Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation

NCT00828009 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT00828009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00828009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Completed
Start date
January 17, 2011
Completion date
May 22, 2019
Enrollment
70 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer